Skip to content

Lisdexamfetamine dimesylate

Vyvanse (lisdexamfetamine dimesylate) is a small molecule pharmaceutical. Lisdexamfetamine dimesylate was first approved as Vyvanse on 2007-02-23. It is used to treat attention deficit disorder with hyperactivity and binge drinking in the USA. Vyvanse's patent is valid until 2023-02-24 (FDA).
Trade Name Vyvanse
Common Name Lisdexamfetamine dimesylate
Indication attention deficit disorder with hyperactivity, binge drinking
Drug Class Amfetamine derivatives
Lisdexamfetamine dimesylate
Get full access now